抗血管内皮増殖因子（抗VEGF）薬の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-14757 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、108ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、抗血管内皮増殖因子（抗VEGF）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。抗血管内皮増殖因子（抗VEGF）薬の種類別市場規模（アゴニスト、アロステリックモジュレーター、キナーゼ阻害剤、モノクローナル抗体、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、TRACON Pharmaceuticals、Santen Oy、Regeneron Pharmaceuticals、Eli Lilly and Company、Bayer、GSK、Novartis、Kanghong Pharmaceuticals、Pfizer、BIOCAD ・地域別グローバル市場分析 2015年-2020年 ・抗血管内皮増殖因子（抗VEGF）薬の北米市場（アメリカ、カナダ、メキシコ） ・抗血管内皮増殖因子（抗VEGF）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・抗血管内皮増殖因子（抗VEGF）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・抗血管内皮増殖因子（抗VEGF）薬の南米市場（ブラジル、アルゼンチン） ・抗血管内皮増殖因子（抗VEGF）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アゴニスト、アロステリックモジュレーター、キナーゼ阻害剤、モノクローナル抗体、その他 ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Market segmentation
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market has been segmented into:
Agonist
Allosteric Modulator
Kinase Inhibitor
Monoclonal Antibody
Others

By Application, Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs has been segmented into:
Hospital
Clinic
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share Analysis
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs are:
Roche
TRACON Pharmaceuticals
Santen Oy
Regeneron Pharmaceuticals
Eli Lilly and Company
Bayer
GSK
Novartis
Kanghong Pharmaceuticals
Pfizer
BIOCAD
Among other players domestic and global, Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Overview
1.1 Product Overview and Scope of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs
1.2 Classification of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by Type
1.2.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type in 2019
1.2.3 Agonist
1.2.4 Allosteric Modulator
1.2.5 Kinase Inhibitor
1.2.6 Monoclonal Antibody
1.2.7 Others
1.3 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market by Application
1.3.1 Overview: Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market by Regions
1.4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 TRACON Pharmaceuticals
2.2.1 TRACON Pharmaceuticals Details
2.2.2 TRACON Pharmaceuticals Major Business
2.2.3 TRACON Pharmaceuticals SWOT Analysis
2.2.4 TRACON Pharmaceuticals Product and Services
2.2.5 TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Santen Oy
2.3.1 Santen Oy Details
2.3.2 Santen Oy Major Business
2.3.3 Santen Oy SWOT Analysis
2.3.4 Santen Oy Product and Services
2.3.5 Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Regeneron Pharmaceuticals
2.4.1 Regeneron Pharmaceuticals Details
2.4.2 Regeneron Pharmaceuticals Major Business
2.4.3 Regeneron Pharmaceuticals SWOT Analysis
2.4.4 Regeneron Pharmaceuticals Product and Services
2.4.5 Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company SWOT Analysis
2.5.4 Eli Lilly and Company Product and Services
2.5.5 Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Product and Services
2.6.4 Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 GSK
2.7.1 GSK Details
2.7.2 GSK Major Business
2.7.3 GSK Product and Services
2.7.4 GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Product and Services
2.8.4 Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Kanghong Pharmaceuticals
2.9.1 Kanghong Pharmaceuticals Details
2.9.2 Kanghong Pharmaceuticals Major Business
2.9.3 Kanghong Pharmaceuticals Product and Services
2.9.4 Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Product and Services
2.10.4 Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 BIOCAD
2.11.1 BIOCAD Details
2.11.2 BIOCAD Major Business
2.11.3 BIOCAD Product and Services
2.11.4 BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Market Share
3.2.2 Top 10 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Market Share by Regions
4.2 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
5 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries
5.1 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
5.2 USA Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
6 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries
6.1 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
6.2 Germany Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
6.4 France Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries
7.1 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
7.2 China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
7.5 India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
8 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries
8.1 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
8.2 Brazil Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by Countries
9.1 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Forecast by Type (2019-2024)
10.3 Agonist Revenue Growth Rate (2015-2025)
10.4 Allosteric Modulator Revenue Growth Rate (2015-2025)
10.5 Kinase Inhibitor Revenue Growth Rate (2015-2025)
10.6 Monoclonal Antibody Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Segment by Application
11.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application (2015-2020)
11.2 Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Forecast (2021-2025)
12.1 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size Forecast (2021-2025)
12.2 Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Forecast by Regions (2021-2025)
12.3 North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
12.6 South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 8. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 11. Roche Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. TRACON Pharmaceuticals Corporate Information, Location and Competitors
Table 13. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 14. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2018-2019)
Table 15. TRACON Pharmaceuticals SWOT Analysis
Table 16. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 17. TRACON Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Santen Oy Corporate Information, Location and Competitors
Table 19. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 20. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 21. Santen Oy SWOT Analysis
Table 22. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 23. Santen Oy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Regeneron Pharmaceuticals Corporate Information, Location and Competitors
Table 25. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 26. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 27. Regeneron Pharmaceuticals SWOT Analysis
Table 28. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 29. Regeneron Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Eli Lilly and Company Corporate Information, Location and Competitors
Table 31. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 32. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 33. Eli Lilly and Company SWOT Analysis
Table 34. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 35. Eli Lilly and Company Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Bayer Corporate Information, Location and Competitors
Table 37. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 38. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 39. Bayer SWOT Analysis
Table 40. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 41. Bayer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. GSK Corporate Information, Location and Competitors
Table 43. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 44. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 45. GSK SWOT Analysis
Table 46. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 47. GSK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Novartis Corporate Information, Location and Competitors
Table 49. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 50. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 51. Novartis SWOT Analysis
Table 52. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 53. Novartis Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Kanghong Pharmaceuticals Corporate Information, Location and Competitors
Table 55. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 56. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 57. Kanghong Pharmaceuticals SWOT Analysis
Table 58. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 59. Kanghong Pharmaceuticals Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Pfizer Corporate Information, Location and Competitors
Table 61. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 62. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 63. Pfizer SWOT Analysis
Table 64. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 65. Pfizer Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. BIOCAD Corporate Information, Location and Competitors
Table 67. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Major Business
Table 68. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Total Revenue (USD Million) (2017-2018)
Table 69. BIOCAD SWOT Analysis
Table 70. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Product and Solutions
Table 71. BIOCAD Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Players (2015-2020)
Table 73. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Players (2015-2020)
Table 74. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Regions (2015-2020)
Table 75. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Regions (2015-2020)
Table 76. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
Table 77. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Table 78. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 80. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Countries (2015-2020)
Table 81. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Table 84. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) by Type (2015-2020)
Table 85. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Type (2015-2020)
Table 86. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Forecast by Type (2021-2025)
Table 87. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue by Application (2015-2020)
Table 88. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Application (2015-2020)
Table 89. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Forecast by Application (2021-2025)
Table 90. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Picture
Figure 2. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Type in 2019
Figure 3. Agonist Picture
Figure 4. Allosteric Modulator Picture
Figure 5. Kinase Inhibitor Picture
Figure 6. Monoclonal Antibody Picture
Figure 7. Others Picture
Figure 8. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Application in 2019
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share in 2019
Figure 21. Global Top 10 Players Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Regions (2015-2020)
Figure 25. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Regions in 2018
Figure 26. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 29. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 31. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Figure 32. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries in 2019
Figure 33. USA Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 34. Canada Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries in 2019
Figure 38. Germany Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 39. UK Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 40. France Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 41. Russia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 42. Italy Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries in 2019
Figure 45. China Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Japan Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 47. Korea Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 48. India Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 50. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Figure 51. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries in 2019
Figure 52. Brazil Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 57. UAE Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Type (2015-2020)
Figure 61. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Type in 2019
Figure 62. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share Forecast by Type (2021-2025)
Figure 63. Global Agonist Revenue Growth Rate (2015-2020)
Figure 64. Global Allosteric Modulator Revenue Growth Rate (2015-2020)
Figure 65. Global Kinase Inhibitor Revenue Growth Rate (2015-2020)
Figure 66. Global Monoclonal Antibody Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Application (2015-2020)
Figure 69. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Share by Application in 2019
Figure 70. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospital Revenue Growth Rate (2015-2020)
Figure 72. Global Clinic Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
Figure 78. Europe Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
Figure 80. South America Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---